Overall, the pathways affected by miR-181b are highly relevant for CLL pathogenesis, and the simultaneous inhibition of Akt and MAPK pathways, together with the repression of anti-apoptotic proteins such as TCL1, Bcl2 and Mcl1, appears to represent a wide and highly effective panel of targets for achieving a strong therapeutic effect, as shown by the fact that several of these pathways are targeted by some of the newly available drugs against CLL [71]. The gene discussed is MCL1; the disease is B-cell chronic lymphocytic leukemia.